Skip to content
value.today
Terrascend logo

Terrascend

TED.F
$146 Mmarket cap on Oct 31, 2026-73.4% since Jan 2024
1M
-11.8%
Compare
World rank
#17,345
Revenue
$261 M
For year ending December-2025
Net income
$-81 M
-31.2% margin
SEC filing
Employees
—

Terrascend in brief

Terrascend is a listed company in the Pharmaceutical industry, based in Canada. It was founded in 2017. Its market value was $146 M on 31 October 2026, which makes it the 17,345th largest listed company in the world and the 617th largest in Canada on this site. In the year to December 2025 it had sales of $261 M and a net loss of $81 M. By market, the largest shares of its 2025 sales came from Canada (under 1%). Its shares trade under the symbol TED.F (Frankfurt).

Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.

About Terrascend

TERRASCEND is a vertically integrated cannabis company providing industry product selection to both the medical and legal adult-use markets. It operations in Pennsylvania, New Jersey, Michigan and California, licensed cultivation and processing operations in Maryland and licensed production in Canada. The headquarters is in Canada.

Terrascend company annual revenue was 247 million USD and annual net loss was -303 million USD for year ending December 2022.

Terrascend timeline

1 events, 2017
  1. 2017
  2. 🏁
    · approximate
    Founded

Events of Terrascend from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$311 M$621 M$932 M$1.2 B2020202120222023202420252026

World rank over time

▲ up 860 places since 2020
2020-01-01: #18298#18,29820202021-01-01: #9267#9,26720212022-01-07: #8702#8,70220222022-12-25: #13888#13,88820222023-07-30: #13501#13,50120232024-01-05: #12031#12,03120242026-09-30: #16984#16,98420262026-10-31: #17438#17,4382026

Rank in Canada: #489 (Jan 2020) · #257 (Jan 2021) · #264 (Jan 2022) · #367 (Dec 2022) · #365 (Jul 2023) · #321 (Jan 2024) · #613 (Sep 2026) · #617 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.5×
Price / book
1.5×
Free cash flow yield
8.8%
Net margin (TTM)
-6.7%
Operating margin
16.1%
Return on equity
-18.1%
Liabilities / assets
82.2%
Net debt
$188M
Revenue growth
-2.8%
R&D / revenue
0.1%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue $132M, net income $-142M$132MFY20Fiscal year ending Dec 2021: revenue $194M, net income $6M$194MFY21Fiscal year ending Dec 2022: revenue $248M, net income $-325M$248MFY22Fiscal year ending Dec 2023: revenue $251M, net income $-87M$251MFY23Fiscal year ending Dec 2024: revenue $268M, net income $-73M$268MFY24Fiscal year ending Dec 2025: revenue $261M, net income $-81M$261MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$261M-2.8%$42M$-81M-31.2%
Dec 2024$268M+7.0%$39M$-73M-27.1%
Dec 2023$251M+1.1%$30M$-87M-34.6%
Dec 2022$248M+27.6%$-336M$-325M-131.3%
Dec 2021$194M+47.0%$23M$6M3.2%
Dec 2020$132M—$21M$-142M-107.7%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$22M$9M$13M$-0.29—
Dec 2024$38M$7M$31M$-0.28—
Dec 2023$27M$5M$23M$-0.34—
Dec 2022$-26M$40M$-66M$-1.35—
Dec 2021$-32M$40M$-72M$0.01—
Dec 2020$-37M$44M$-81M$-1.03—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$267M
Net income, trailing 12 months
$-18M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $55M, net income $-30M$55MDec ’24Three months to Mar 2025: revenue $64M, net income $-12M$64MMar ’25Three months to Jun 2025: revenue $65M, net income $-48M$65MJun ’25Three months to Sep 2025: revenue $65M, net income $-25M$65MSep ’25Three months to Dec 2025 (from the annual report): revenue $66M, net income $4M$66MDec ’25Three months to Mar 2026: revenue $66M, net income $-8M$66MMar ’26Three months to Jun 2026: revenue $67M, net income $-8M$67MJun ’26Three months to Sep 2026: revenue $68M, net income $-5M$68MSep ’26

Latest quarter to Sep 2026: revenue $68M (+4.8% on a year earlier), net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Terrascend with the US Securities and Exchange Commission.

Annual results

Revenue
$261 M
Operating income
$42 M
Net income
$-81 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$557 M
Total liabilities
$458 M
Total equity
$99 M

As of December-2025

Insider trading at Terrascend#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
2
since
Terrascend: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Lynn K. GefenChief People and Legal OfficerShares withheld for tax-7,412$0.660$5 K1.08 MForm 4
filed Ziad GhanemPresident and CEOShares withheld for tax-22,017$0.660$15 K2.86 MForm 4
filed Lynn K. GefenChief People and Legal OfficerShares withheld for tax-5,591$0.620$3 K1.09 MForm 4
filed Ziad GhanemPresident and CEOShares withheld for tax-9,998$0.620$6 K2.89 MForm 4
filed Lynn K. GefenChief People and Legal OfficerShares withheld for tax-50,879$0.680$35 K1.09 MForm 4
filed Ziad GhanemPresident and CEOShares withheld for tax-105,051$0.680$71 K2.90 MForm 4
filed Lynn K. GefenChief People and Legal OfficerGrant or award+540,254——1.15 MForm 4
filed Ziad GhanemPresident and CEOGrant or award+1.39 M——3.00 MForm 4

Markets and events: Terrascend#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Buybacks, Q3 2026
$0.6M
Q3 2026
Terrascend share buybacks by quarter
Buybacks, quarterFiscalSpent
Q3 2026Q3 2026$0.6M
Q2 2026Q2 2026$0.3M
Q1 2026Q1 2026$0.1M
Q4 2025Q4 2025$0M
Q3 2025Q3 2025$0M
Q2 2025Q2 2025$0.1M
Q1 2025Q1 2025$0.2M
Q4 2024Q4 2024$0.1M

Terrascend scorecard#

Passes 10 of the 26 checks that could be worked out: strongest in valuation (3 of 6), weakest in growth (2 of 6). Fiscal year 2025; market cap of Oct 31, 2026.

  • Valuation3 of 6
  • Growth2 of 6
  • Profitability2 of 5
  • Financial health2 of 6
  • Shareholder returns1 of 3

Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Terrascend's statements, beside the median of Pharmaceutical.

Terrascend: main financial ratios in 2025
Ratio2025Median of peers
Operating margin16.1%1.8%
Net margin-31.2%-1.5%
Return on equity-59.0%-0.9%
Revenue growth, 3 years a year1.7%2.5%
Revenue growth-2.8%7.3%
Debt to equity2.28×0.66×

4of 9on the Piotroski tests of financial strength

  • Revenue fell 2.8% against the year before.
  • Net loss of $81 million, the 4th loss-making year in a row.
  • Operating income covers the interest bill only 1.5 times.
  • Goodwill and intangibles ($277 million) exceed shareholders' equity ($99 million).

Terrascend: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Terrascend: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue261268r251r248194132
Cost of revenue124132r112r1468246
Gross profit136136r138r10211386
Research and development—————0.1
Selling, general and administrative——1151167561
Selling and marketing——9.7101.91.7
General and administrative8691r84r1167561
Operating expenses9497r108r4379065
Operating income4239r30r−3362321
Interest expense and finance costs2927r31r27212.0
Other non-operating income (expense)0.90.9r−0.8r0.20.2−0.4
Income before tax5.04.2r−4.2r−31045−117
Income tax2925r23r−112911
Income from continuing operations−29−28r−36r−30413−139
Income from discontinued operations−57−52−59r−26−9.5−15
Minority interests' share of net income4.97.68.84.63.0—
Net income attributable to shareholders−81−73−87−3256.1−142
Earnings per share, basic-0.29-0.28-0.34r-1.350.02-1.03
Earnings per share, diluted-0.29-0.28-0.34r-1.350.01-1.03
Shares, weighted average (basic)301292279244181150
Shares, weighted average (diluted)301292279244209150
Balance sheet
Cash and cash equivalents3726222680—
Short-term investments0.41.71.93.6——
Receivables1720r192212r—
Inventory3440r524636r—
Other current assets8.65.1r4.95.5r5.0r—
Current assets110177r103122172r—
Property, plant and equipment130124r196216112r—
Right-of-use (leased) assets2729r432943r—
Goodwill110107107r909073
Other intangible assets167170216240168r—
Non-current assets447430r564580409r—
Total assets557607r667702582r—
Accounts payable4040r504428r—
Debt due within a year——12639——
Current liabilities8091r20713866r—
Lease liabilities (non-current)2931r453231—
Non-current liabilities378339r219243287r—
Total liabilities458430r426380353r—
Retained earnings−865−779−704−618−315—
Minority interests1.5−0.1−1.82.45.43.8
Total equity99177241321229−13
Total liabilities and equity557607r667702582r—
Shares outstanding309293288260191—
Cash-flow statement
Depreciation and amortization5.45.1r5.8r9.75.53.9
Share-based compensation5.09.77.7121510
Cash from operating activities223827−26−32−37
Capital expenditure−8.6−6.9r−4.9r−40−40−44
Intangible assets bought−0.7−1.2−1.7r−2.3−0.4−0.8
Cash from investing activities−15−12−16−28−132−46
Debt issued7912924430.8196
Debt repaid−70−137r−43r−42−4.5−49
Shares bought back−0.4−0.2————
Cash from financing activities4.2−25−133.7182133
Report10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

As of Sep 30, 2026

What Terrascend sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Countries and regions

As of Dec 31, 2025

Where Terrascend operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 61 subsidiaries on file.

Terrascend: countries of operation
CountryPresenceRevenue there
🇨🇦 CanadaHeadquarters1 subsidiary$1 M0.3%
🇺🇸 USA60 subsidiaries—

Events at Terrascend#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Restructuring 1 · Directors and officers 6 · Material agreement 3 · Agreement ended 3 · New debt 3 · Unregistered share sale 4 · Shareholder vote 4 · Results announced 13

Terrascend: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Shareholder vote8-K
Directors and officersResults announced8-K
Material agreementNew debtUnregistered share sale8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Unregistered share sale8-K
Results announced8-K
Results announced8-K
Material agreementAgreement endedNew debt8-K
Restructuring8-K
Directors and officersShareholder vote8-K
Directors and officersUnregistered share sale8-K
Unregistered share saleResults announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Agreement ended8-K
Results announced8-K
Material agreementAgreement endedNew debt8-K
Shareholder vote8-K
Results announced8-K

As of Nov 5, 2026

Acquisitions and funding#

10 acquisitions, $516 M paid where reported · 7 private funding rounds before listing

Businesses it acquired

Acquisitions by Terrascend
AcquiredAcquisition dateCompletionPriceStakeSource
Ratio Cannabis LLC2025—$10 M—Annual report
Peninsula2023—$15 M100%Annual report
Herbiculture2023—$8 M100%Annual report
Blue Ridge2023—$6 M100%Annual report
Gage Growth Corp2022—$330 M—Annual report
Pinnacle2022—$31 M—Annual report
KISA Enterprises MI, LLC and KISA Holdings, LLC2022—$31 M—Annual report
AMMD2022—$10 M100%Annual report
New Jersey Partnership2021—$50 M93.75%Annual report
HMS2021—$24 M100%Annual report

Private share sales · funding history

Private share sales of Terrascend
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2026$22 MPrivate placement after listing$10 to $50 million8debt, optionsSEC
May 2020$21 MNo. 7$10 to $50 million25equity, optionsSEC
Jan 2020$4 MNo. 6$2 to $10 million2debt, optionsSEC
Jan 2020$4 MNo. 5$2 to $10 million10debt, optionsSEC
Dec 2019$23 MNo. 4$10 to $50 million24debt, optionsSEC
Nov 2019$2 MNo. 3$2 to $10 million2debt, optionsSEC
Jun 2019$38 MIssued in a merger or acquisition$10 to $50 million8equitySEC
May 2019$20 MNo. 2$10 to $50 million13equitySEC
May 2019$23 MNo. 1$10 to $50 million50equitySEC

How Terrascend compares in Pharmaceutical

  • Market cap$146 M · higher than 21% of 393
  • Revenue$261 M · higher than 33% of 324
  • Net margin-6.7% · higher than 21% of 313
  • Revenue growth-2.8% · higher than 19% of 107
  • Price / sales0.6× · lower than 93% of 219
  • Price / book1.5× · lower than 67% of 207
  • FCF yield8.8% · higher than 81% of 69

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
Terrascend🇨🇦$146 M—-6.7%-2.8%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Oct 31, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 22, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Terrascend? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Terrascend's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Terrascend? Suggest a correction